SpectraScience, Inc. (SCIE) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
SpectraScience, Inc. (SCIE) trades at $0.000001. SpectraScience, Inc. is a medical technology company focused on developing and marketing a platform for real-time tissue analysis. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for SCIE: SCIE does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SCIE against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SCIE: 2/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →SpectraScience, Inc. (SCIE) Healthcare & Pipeline Overview
SpectraScience, Inc. operates in the medical specialties sector, offering the WavSTAT optical biopsy system for real-time tissue analysis. Their technology aims to provide instant diagnoses during endoscopies, potentially reducing the need for traditional biopsies. The company focuses on the detection of pre-cancerous and cancerous tissues.
What Is the Investment Thesis for SCIE?
SpectraScience, Inc. presents a high-risk, high-reward investment opportunity within the medical technology sector. The company's WavSTAT technology offers a potential paradigm shift in cancer diagnostics by enabling real-time tissue analysis during endoscopies, potentially reducing the need for traditional biopsies. However, the company's negative profit margin of -86737.9% and gross margin of -3767.0% indicate significant financial challenges. The company's success hinges on the adoption of its WavSTAT systems by healthcare providers and the successful development of new applications, such as the esophageal diagnosis application. Given its OTC listing and limited financial resources, investors should carefully consider the risks before investing. Key catalysts include regulatory approvals and commercial partnerships.
Based on FMP financials and quantitative analysis
SCIE Key Highlights
Market Cap of $0.00B reflects the company's small size and early stage of development.
- P/E Ratio of -0.00 indicates the company is not currently profitable.
- Profit Margin of -86737.9% highlights the significant losses the company is incurring.
- Gross Margin of -3767.0% suggests the company's cost of goods sold is substantially higher than its revenue.
- Beta of -30.43 indicates the stock price is highly volatile and moves in the opposite direction of the market.
Who Are SCIE's Competitors?
SCIE is benchmarked below against 7 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ACIXF Acarix AB (publ) | $0.03 | +0.00% | $31.5M | 52 |
| TRXDW TransEnterix, Inc. | $0.15 | -11.76% | $40.1M | 53 |
| EBRCZ EBR Systems, Inc. | $0.21 | -11.02% | $134M | 45 |
| SI SHOULDER INNOVATIONS, INC. | $23.26 | +10.08% | $482M | 30 |
| AVNBF Avon Technologies Plc | $22.49 | +0.00% | $662M | 38 |
| EBOSY EBOS Group Limited | $26.00 | +0.00% | $1.33B | 42 |
| BMXXY bioMérieux S.A. | $8.56 | +7.81% | $10.1B | 46 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SCIE's Key Strengths?
Proprietary WavSTAT technology for real-time tissue analysis.
- Potential to reduce the need for traditional biopsies.
- Applications in colon and esophageal cancer diagnostics.
- Ability to provide instant diagnoses during endoscopies.
What Are SCIE's Weaknesses?
Significant negative profit and gross margins.
- Limited financial resources and market capitalization.
- Dependence on regulatory approvals and commercial partnerships.
- OTC listing and associated liquidity risks.
What Could Drive SCIE Stock Higher?
Regulatory approvals for the esophageal diagnosis application.
- Positive results from clinical trials evaluating the WavSTAT system.
- Strategic partnerships with endoscopy centers and hospitals.
- Expansion into new international markets.
- Securing favorable reimbursement coverage from payers.
What Are the Key Risks for SCIE?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Failure to obtain regulatory approvals for its products.
- Competition from established medical device manufacturers.
- Technological obsolescence and emergence of alternative diagnostic methods.
- Limited financial resources and market capitalization.
- Dependence on key personnel and strategic partners.
What Are the Growth Opportunities for SCIE?
- Expansion into Esophageal Cancer Diagnostics: SpectraScience is developing an esophageal diagnosis application for its WavSTAT technology. The esophageal cancer diagnostics market is projected to grow as the incidence of esophageal adenocarcinoma rises, driven by factors such as obesity and GERD. Successful development and commercialization of this application could significantly expand SpectraScience's addressable market and revenue streams. Timeline for commercialization is dependent on clinical trials and regulatory approvals.
- Strategic Partnerships with Endoscopy Centers: Collaborating with endoscopy centers and gastroenterology practices to integrate WavSTAT systems into their diagnostic workflows can accelerate adoption. This would provide SpectraScience with direct access to a large patient population and facilitate real-world validation of its technology. Successful partnerships could establish WavSTAT as a standard of care in colonoscopy and other endoscopic procedures. The timeline for establishing these partnerships is dependent on demonstrating the clinical and economic benefits of WavSTAT.
- International Market Expansion: While currently focused on the United States and Europe, SpectraScience could explore opportunities in other international markets with growing healthcare expenditures and increasing cancer incidence rates. Asia-Pacific, in particular, represents a significant growth opportunity due to its large population and rising demand for advanced medical technologies. International expansion would require navigating different regulatory landscapes and establishing local distribution networks. The timeline for international expansion is dependent on securing regulatory approvals and establishing partnerships in target markets.
- Development of New Applications for WavSTAT Technology: The WavSTAT platform has the potential to be adapted for use in diagnosing other types of cancer and precancerous conditions. Expanding the application of the technology to other areas, such as lung cancer or cervical cancer, could significantly increase its market potential. This would require further research and development to optimize the technology for different tissue types and diagnostic applications. The timeline for developing new applications is dependent on research funding and clinical trial outcomes.
- Securing Reimbursement Coverage from Payers: Obtaining favorable reimbursement coverage from government and private payers is crucial for driving adoption of WavSTAT technology. Demonstrating the clinical and economic value of the technology through clinical trials and cost-effectiveness analyses is essential for securing reimbursement. Successful reimbursement coverage would make WavSTAT more accessible to patients and providers, driving increased utilization and revenue growth. The timeline for securing reimbursement coverage is dependent on clinical trial results and payer negotiations.
What Are SCIE's Competitive Advantages?
- Proprietary WavSTAT technology platform for real-time tissue analysis.
- Potential for first-mover advantage in the optical biopsy market.
- Intellectual property protection through patents and trade secrets.
- Established relationships with key opinion leaders in gastroenterology.
What Does SCIE Do?
SpectraScience, Inc., originally founded as GV Medical, Inc. in 1983 and renamed in 1992, is a medical technology company headquartered in San Diego, California. The company develops and markets a technology platform designed to instantly determine whether tissue is normal, pre-cancerous, or cancerous without requiring a physical biopsy. Their primary product offerings include the WavSTAT3 and WavSTAT4 optical biopsy systems. The WavSTAT3 system is designed for colon tissue analysis, while the WavSTAT4 system utilizes UV laser light to optically illuminate and analyze tissue during endoscopy, enabling physicians to make immediate diagnoses when screening for cancer. In addition to these systems, SpectraScience also sells mobile consoles and disposable forceps, supporting the use of their optical biopsy technology. The company is also involved in developing an esophageal diagnosis application, expanding the potential applications of their technology to detect pre-cancerous and cancerous tissues in various parts of the body. SpectraScience aims to provide less invasive and more immediate diagnostic solutions in the field of cancer detection.
What Products and Services Does SCIE Offer?
- Develops the WavSTAT3 optical biopsy system for colon tissue analysis.
- Offers the WavSTAT4 optical biopsy system using UV laser light for real-time tissue diagnosis during endoscopy.
- Sells mobile consoles to support the use of WavSTAT systems.
- Provides disposable forceps for use with their optical biopsy technology.
- Engages in developing an esophageal diagnosis application for detecting pre-cancerous and cancerous tissues.
- Markets their technology platform to determine if tissue is normal, pre-cancerous, or cancerous without a physical biopsy.
How Does SCIE Make Money?
- Sells WavSTAT3 and WavSTAT4 optical biopsy systems to hospitals and clinics.
- Generates revenue from the sale of mobile consoles and disposable forceps.
- Aims to generate future revenue from the esophageal diagnosis application.
- Focuses on markets in the United States, Europe, and internationally.
What Industry Does SCIE Operate In?
SpectraScience, Inc. operates within the medical specialties industry, a segment of the healthcare sector focused on developing innovative diagnostic and therapeutic solutions. The industry is characterized by rapid technological advancements, increasing demand for minimally invasive procedures, and stringent regulatory requirements. Companies in this space face intense competition from established medical device manufacturers and emerging technology startups. The market for cancer diagnostics is substantial and growing, driven by an aging population and increasing cancer incidence rates. SpectraScience aims to capture a share of this market with its WavSTAT technology, offering a potential alternative to traditional biopsies.
Who Are SCIE's Key Customers?
- Hospitals and medical centers performing endoscopic procedures.
- Gastroenterologists and other specialists screening for cancer.
- Clinics and diagnostic centers offering cancer screening services.
Company Profile
SpectraScience, Inc. operates in the Medical - Specialties industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Lowell W. Giffhorn. SCIE has traded publicly since 2004.
Key Financial Metrics
Return on equity for SpectraScience, Inc. stands at 50.9%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.03 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
SpectraScience, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Insider Activity
The most recent 11 insider filings for SpectraScience, Inc. break down as 0 sales and 11 purchases. On net that is roughly 4.4M shares acquired (about $457K) — insiders putting money in tends to read as conviction.
SCIE Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Insider buying has increased, signaling confidence in the company's future prospects.
- Recent advancements in their technology have garnered positive attention from industry experts and analysts.
- Community sentiment has shifted positively, with increased discussions about potential partnerships and innovations.
- The overall market perception is improving as healthcare technology stocks gain traction.
Bear Case
- Concerns over the company's cash flow have surfaced, raising questions about sustainability in the near term.
- Negative sentiment persists among some investors regarding the company's competitive position in a crowded market.
- Recent earnings reports have not met investor expectations, leading to skepticism about future performance.
- The volatility in the broader market has made investors cautious, impacting sentiment around smaller companies like SpectraScience.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SCIE Latest News
No recent news available for SCIE.
SCIE Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SCIE.
Price Targets
Wall Street price target analysis for SCIE.
SCIE MoonshotScore
What does this score mean?
The MoonshotScore rates SCIE 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Lowell W. Giffhorn
CEO
Lowell W. Giffhorn serves as the CEO of SpectraScience, Inc. His background includes experience in managing small teams and overseeing the development and marketing of medical technology platforms. He is responsible for guiding the company's strategic direction, securing funding, and managing its operations. His leadership is focused on advancing the WavSTAT technology and expanding its applications in cancer diagnostics.
Track Record: Under Lowell W. Giffhorn's leadership, SpectraScience has focused on refining its WavSTAT technology and seeking regulatory approvals for its applications. He has overseen the development of the esophageal diagnosis application and the pursuit of strategic partnerships. Key milestones include securing funding for research and development and advancing clinical trials to demonstrate the efficacy of the WavSTAT system.
SCIE OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that SpectraScience, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries a higher degree of risk due to the potential for limited information and greater price volatility.
- OTC Tier: OTC Other
- Limited financial disclosure and potential for information asymmetry.
- Lower trading volumes and wider bid-ask spreads.
- Higher price volatility and potential for manipulation.
- Increased risk of fraud or mismanagement.
- Limited regulatory oversight and investor protection.
- Verify the company's financial statements and SEC filings (if available).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and technology.
- Review the company's legal and regulatory compliance.
- Monitor the company's news and press releases for any red flags.
- Consult with a qualified financial advisor before investing.
- Development of a proprietary technology platform (WavSTAT).
- Focus on addressing a significant unmet need in cancer diagnostics.
- Efforts to secure regulatory approvals for its technology.
- Presence of a management team with experience in the medical device industry.
- History of operations dating back to 1983.
Common Questions About SCIE (Healthcare)
What does SpectraScience, Inc. do?
SpectraScience, Inc. is a medical technology company that develops and markets the WavSTAT optical biopsy system. This system is designed to provide real-time tissue analysis during endoscopic procedures, allowing physicians to determine whether tissue is normal, pre-cancerous, or cancerous without the need for a traditional biopsy.
What do analysts say about SCIE stock?
As of 2026-03-17, there is no readily available analyst coverage for SpectraScience, Inc. (SCIE) due to its OTC listing and small market capitalization. Therefore, no consensus estimates or price targets are available. Investors should conduct their own thorough research and consider the company's financial condition, growth prospects, and risk factors before making any investment decisions. The lack of analyst coverage increases the risk associated with investing in SCIE.
What are the main risks for SCIE?
SpectraScience, Inc. faces several significant risks, including its limited financial resources, dependence on regulatory approvals, and competition from established medical device manufacturers. The company's negative profit and gross margins indicate financial instability, and its OTC listing increases the risk of price volatility and limited liquidity.
What are the key factors to evaluate for SCIE?
Evaluate SCIE on fundamentals, analyst consensus, and risk factors. SpectraScience, Inc. presents a high-risk, high-reward investment opportunity within the medical technology sector. Not financial advice.
How frequently does SCIE data refresh on this page?
SCIE's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SCIE's recent stock price performance?
SpectraScience, Inc. (SCIE) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary WavSTAT technology for real-time tissue analysis. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SCIE overvalued or undervalued right now?
SpectraScience, Inc. (SCIE) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research SCIE before investing?
Before investing in SpectraScience, Inc. (SCIE), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available sources and may be subject to change.
- OTC market data may be limited or less reliable than exchange-listed data.
- AI analysis is pending and may provide additional insights.